Top

Published in:

01-03-2014 | Original Article

Higher serum uric acid and lipoprotein(a) are correlated with coronary spasm

Authors: Masami Nishino, Naoki Mori, Takahiro Yoshimura, Daisuke Nakamura, Yasuharu Lee, Masayuki Taniike, Nobuhiko Makino, Hiroyasu Kato, Yasuyuki Egami, Ryu Shutta, Jun Tanouchi, Yoshio Yamada

Published in: Heart and Vessels | Issue 2/2014

Abstract

It has been reported that a major cause of coronary vasospastic angina (VSA) is endothelial dysfunction of the coronary artery. On the other hand, some studies showed that serum uric acid and lipoprotein(a) are correlated with endothelial dysfunction. Thus, we examined whether uric acid and lipoprotein(a), are correlated with VSA. Four hundred forty-one patients with suspected VSA who underwent a coronary angiogram with acetylcholine provocation (ACh test) during an 8-year period were enrolled. We divided them into a VSA group, who showed coronary spasm by the ACh test, and an atypical chest pain (ACP) group, who showed negative ACh test. We compared serum markers between the two groups, including low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, high-sensitivity C-reactive protein (hs-CRP), lipoprotein(a), fibrinogen, total plasminogen activator inhibitor-1, and uric acid. Uric acid, hs-CRP, and lipoprotein(a) were significantly higher in the VSA group than in the ACP group (all P < 0.05) while there were no significant differences in the other parameters. Multivariate analyses identified uric acid and lipoprotein(a) as significant independent markers for VSA. Uric acid and lipoprotein(a) are correlated with VSA, and medical intervention to decrease uric acid and lipoprotein(a) might be effective in controlling VSA.

Yasue H, Horio Y, Nakamura N, Fujii H, Imoto N, Sonoda R, Kugiyama K, Obata K, Morikami Y, Kimura T (1986) Induction of coronary artery spasm by acetylcholine in patients with variant angina: possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm. Circulation 74:955–963PubMedCrossRef

Kaski JC, Crea F, Meran D, Rodriguez L, Araujo L, Chierchia S, Davies G, Maseri A (1986) Local coronary supersensitivity to diverse vasoconstrictive stimuli in patients with variant angina. Circulation 74:1255–1265PubMedCrossRef

Yasue H, Takizawa A, Nagao M, Nishida S, Horie M, Kubota J, Omote S, Takaoka K, Okumura K (1988) Long-term prognosis for patients with variant angina and influential factors. Circulation 78:1–9PubMedCrossRef

Myerburg RJ, Kessler KM, Mallon SM, Cox MM, deMarchena E, Interian AJ, Castellanos A (1992) Life-threatening ventricular arrhythmias in patients with silent myocardial ischemia due to coronary-artery spasm. N Engl J Med 326:1451–1455PubMedCrossRef

Bory M, Panagides D, Desfossez L (1993) Coronary artery spasm in myocardial infarction. Lancet 342:436PubMedCrossRef

Kugiyama K, Ohgushi M, Motoyama T, Sugiyama S, Ogawa H, Yoshimura M, Inobe Y, Hirashima O, Kawano H, Soejima H, Yasue H (1997) Nitric oxide-mediated flow-dependent dilation is impaired in coronary arteries in patients with coronary spastic angina. J Am Coll Cardiol 30:920–926PubMedCrossRef

Kanellis J, Kang DH (2005) Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 25:39–42PubMedCrossRef

Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ (2005) Hyperuricemia induces endothelial dysfunction. Kidney Int 67:1739–1742PubMedCrossRef

Sanchez-Lozada LG, Soto V, Tapia E, Avila-Casado C, Sautin YY, Nakagawa T, Franco M, Rodriguez-Iturbe B, Johnson RJ (2008) Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Ren Physiol 295:F1134–F1141CrossRef

10.

Tsuchida K, Hori T, Tanabe N, Makiyama Y, Ozawa T, Saigawa T, Watanabe R, Tanaka T, Nasuno A, Fukunaga H, Mezaki T, Nakamura Y, Aizawa Y (2005) Relationship between serum lipoprotein(a) concentrations and coronary vasomotion in coronary spastic angina. Circ J 69:521–525PubMedCrossRef

11.

Tsurumi Y, Nagashima H, Ichikawa K, Sumiyoshi T, Hosoda S (1995) Influence of plasma lipoprotein (a) levels on coronary vasomotor response to acetylcholine. J Am Coll Cardiol 26:1242–1250PubMedCrossRef

12.

Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Rother J, Wilson PW (2006) International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295:180–189PubMedCrossRef

13.

(2002) New criteria for ‘obesity disease’ in Japan. Circ J 66:987–992

14.

Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463PubMedCrossRef

15.

Jcs JWG (2010) Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2008): digest version. Circ J 74:1745–1762CrossRef

16.

Crea F, Lanza GA (2011) New light on a forgotten disease: vasospastic angina. J Am Coll Cardiol 58:1238–1240PubMedCrossRef

17.

Yasue H, Kugiyama K (1997) Coronary spasm: clinical features and pathogenesis. Intern Med 36:760–765PubMedCrossRef

18.

Shimokawa H (2000) Cellular and molecular mechanisms of coronary artery spasm: lessons from animal models. Jpn Circ J 64:1–12PubMedCrossRef

19.

Kugiyama K, Yasue H, Okumura K, Ogawa H, Fujimoto K, Nakao K, Yoshimura M, Motoyama T, Inobe Y, Kawano H (1996) Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation 94:266–271PubMedCrossRef

20.

Haberland ME, Fless GM, Scanu AM, Fogelman AM (1992) Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. J Biol Chem 267:4143–4151PubMed

21.

McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM (1987) cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330:132–137PubMedCrossRef

22.

Hajjar KA, Gavish D, Breslow JL, Nachman RL (1989) Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 339:303–305PubMedCrossRef

23.

Sandholzer C, Hallman DM, Saha N, Sigurdsson G, Lackner C, Csaszar A, Boerwinkle E, Utermann G (1991) Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet 86:607–614PubMedCrossRef

24.

Abe A, Noma A (1992) Studies on apolipoprotein(a) phenotypes. Part 1. Phenotype frequencies in a healthy Japanese population. Atherosclerosis 96:1–8PubMedCrossRef

25.

Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M (2003) Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41:1183–1190PubMedCrossRef

26.

Senmaru T, Fukui M, Tanaka M, Sakabe K, Ushigome E, Asano M, Yamazaki M, Hasegawa G, Nakamura N (2012) N-terminal pro-brain natriuretic peptide could be a marker of subclinical atherosclerosis in patients with type 2 diabetes. Heart Vessels. doi:10.1007/s00380-011-0227-0 PubMed

27.

Mineoka Y, Fukui M, Tanaka M, Tomiyasu K, Akabame S, Nakano K, Yamazaki M, Hasegawa G, Oda Y, Nakamura N (2012) Relationship between cardio-ankle vascular index (CAVI) and coronary artery calcification (CAC) in patients with type 2 diabetes mellitus. Heart Vessels 27:160–165PubMedCrossRef

28.

Waring WS, Maxwell SR, Webb DJ (2002) Uric acid concentrations and the mechanisms of cardiovascular disease. Eur Heart J 23:1888–1889PubMedCrossRef

29.

Mercuro G, Vitale C, Cerquetani E, Zoncu S, Deidda M, Fini M, Rosano GM (2004) Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol 94:932–935PubMedCrossRef

30.

Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD (2002) Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 106:221–226PubMedCrossRef

31.

Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, Schuler G, Coats AJ, Anker SD, Hambrecht R (2002) Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 105:2619–2624PubMedCrossRef

32.

Johnson WD, Kayser KL, Brenowitz JB, Saedi SF (1991) A randomized controlled trial of allopurinol in coronary bypass surgery. Am Heart J 121:20–24PubMedCrossRef

33.

Tabayashi K, Suzuki Y, Nagamine S, Ito Y, Sekino Y, Mohri H (1991) A clinical trial of allopurinol (Zyloric) for myocardial protection. J Thorac Cardiovasc Surg 101:713–718PubMed

34.

Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, Marban E, Hare JM (2001) Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 104:2407–2411PubMedCrossRef

35.

Noman A, Ang DS, Ogston S, Lang CC, Struthers AD (2010) Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 375:2161–2167PubMedCentralPubMedCrossRef

36.

Rajendra NS, Ireland S, George J, Belch JJ, Lang CC, Struthers AD (2011) Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J Am Coll Cardiol 58:820–828PubMedCrossRef

37.

Rodrigues TC, Maahs DM, Johnson RJ, Jalal DI, Kinney GL, Rivard C, Rewers M, Snell-Bergeon JK (2010) Serum uric acid predicts progression of subclinical coronary atherosclerosis in individuals without renal disease. Diabetes Care 33:2471–2473PubMedCentralPubMedCrossRef

38.

Sugiishi M, Takatsu F (1993) Cigarette smoking is a major risk factor for coronary spasm. Circulation 87:76–79PubMedCrossRef

39.

Teragawa H, Kato M, Yamagata T, Matsuura H, Kajiyama G (2000) The preventive effect of magnesium on coronary spasm in patients with vasospastic angina. Chest 118:1690–1695PubMedCrossRef

40.

Yasue H, Mizuno Y, Harada E, Itoh T, Nakagawa H, Nakayama M, Ogawa H, Tayama S, Honda T, Hokimoto S, Ohshima S, Hokamura Y, Kugiyama K, Horie M, Yoshimura M, Harada M, Uemura S, Saito Y (2008) Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers. J Am Coll Cardiol 51:1742–1748PubMedCrossRef

Title: Higher serum uric acid and lipoprotein(a) are correlated with coronary spasm
Authors: Masami Nishino
Naoki Mori
Takahiro Yoshimura
Daisuke Nakamura
Yasuharu Lee
Masayuki Taniike
Nobuhiko Makino
Hiroyasu Kato
Yasuyuki Egami
Ryu Shutta
Jun Tanouchi
Yoshio Yamada
Publication date: 01-03-2014
Publisher: Springer Japan
Published in: Heart and Vessels / Issue 2/2014
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-013-0346-x

2024 ASCO Annual Meeting

Springer Medicine

Higher serum uric acid and lipoprotein(a) are correlated with coronary spasm

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Growth differentiation factor 15 can distinguish between hypertrophic cardiomyopathy and hypertensive hearts

Benefits of dual-axis rotational coronary angiography in routine clinical practice

Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects

Erratum to: Elevation of urinary liver-type fatty acid-binding protein as predicting factor for occurrence of contrast-induced acute kidney injury and its reduction by hemodiafiltration with blood suction from right atrium

Greater insulin resistance indicates decreased diurnal variation in the QT interval in patients with type 2 diabetes

Erratum to: Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study